1017 related articles for article (PubMed ID: 26933765)
1. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
Jackson AL; Eisenhauer EL; Herzog TJ
Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
[TBL] [Abstract][Full Text] [Related]
6. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
Monk BJ; Pujade-Lauraine E; Burger RA
Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
Gadducci A; Lanfredini N; Sergiampietri C
Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibitors for the treatment of ovarian cancer.
Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
[TBL] [Abstract][Full Text] [Related]
11. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
Secord AA; Nixon AB; Hurwitz HI
Gynecol Oncol; 2014 Nov; 135(2):349-58. PubMed ID: 25178997
[TBL] [Abstract][Full Text] [Related]
12. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
14. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.
Khosravi-Shahi P; Cabezon-Gutierrez L
Anticancer Agents Med Chem; 2012 Oct; 12(8):982-7. PubMed ID: 22263801
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
Wang X; Zhu Q; Lin Y; Wu L; Wu X; Wang K; He Q; Xu C; Wan X; Wang X
Br J Cancer; 2017 Oct; 117(9):1371-1382. PubMed ID: 28898232
[TBL] [Abstract][Full Text] [Related]
18. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
20. Epithelial ovarian cancer: focus on targeted therapy.
Pliarchopoulou K; Pectasides D
Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]